Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

Filippo Pietrantonio, MD
Published: Wednesday, Aug 10, 2016


Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the benefit of a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).  
 
If this nomogram were to be implemented in clinical trial assessment or inclusion criteria will help enroll patients that can be treated effectively and will most benefit from treatment.
  
The nomogram relies on four variable that impact survival; ECOG performance status, primary tumor resection, LDH value, peritoneal disease. These variables are very easy to collect in daily clinical practice, said Pietrantonio.
 

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the benefit of a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).  
 
If this nomogram were to be implemented in clinical trial assessment or inclusion criteria will help enroll patients that can be treated effectively and will most benefit from treatment.
  
The nomogram relies on four variable that impact survival; ECOG performance status, primary tumor resection, LDH value, peritoneal disease. These variables are very easy to collect in daily clinical practice, said Pietrantonio.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x